Antimony Trisulfide Berberis Vulgaris Root Bark Br
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Antimony Trisulfide Berberis Vulgaris Root Bark Br
- Homeopathic Multi-Ingredient Formula (23 Components): No TxGNN Repurposing Prediction Available
Homeopathic Multi-Ingredient Formula (23 Components): No TxGNN Repurposing Prediction Available
One-Sentence Summary
This product is a complex homeopathic combination formula containing 23 botanical, mineral, and biological ingredients — including Valerian, Passiflora incarnata, Digitalis, Datura stramonium, and Nux vomica — with no conventional pharmacological indication on record. The TxGNN model was unable to generate a repurposing prediction for this entry, as the product lacks a DrugBank identifier, conventional mechanism of action data, and any registered indication that could serve as a graph node in the knowledge graph. With 0 clinical trials and 0 publications linked to this specific formulation, the current evidence base is insufficient to support a repurposing analysis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no registered indication found |
| Predicted New Indication | None — TxGNN did not return a prediction |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only; in this case, no prediction returned) |
| Taiwan Market Status | ✗ Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
This product is a homeopathic multi-ingredient formula composed of 23 substances. Several are well-known classical homeopathic remedies (Pulsatilla vulgaris, Sepia officinalis, Graphite, Lycopodium clavatum); others are herbal agents with documented pharmacological activity at conventional doses (Valerian, Passiflora incarnata, Scutellaria lateriflora, Hops); and a subset are highly toxic plants used exclusively in extreme homeopathic dilution (Datura stramonium, Strychnos nux-vomica, Digitalis).
The TxGNN knowledge graph operates at the level of single chemical entities mapped to DrugBank nodes. This product has no DrugBank ID, no conventional approved indication, and no mechanism of action on record — meaning it cannot be anchored to the drug–disease graph. As a result, the prediction pipeline returned no candidates.
Because homeopathic combination products are not represented in the biomedical knowledge graph used by TxGNN, the absence of a prediction is expected and not a data error. Any repurposing claim for this formulation would need to be built from first principles, starting with individual active ingredient identification and dose characterisation.
Clinical Trial Evidence
Currently no related clinical trials registered for this specific multi-ingredient formulation.
Literature Evidence
Currently no related literature available for this specific multi-ingredient formulation.
Taiwan Market Information
This product has no licenses registered with the Taiwan FDA (TFDA). It is currently not marketed in Taiwan.
Safety Considerations
Please refer to the package insert for safety information.
Note for reviewers: Several ingredients in this formula carry significant intrinsic toxicity at non-homeopathic doses — notably Digitalis (cardiac glycosides), Datura stramonium (anticholinergic alkaloids), Strychnos nux-vomica (strychnine), and Toxicodendron pubescens (urushiol). If this product is ever evaluated at non-homeopathic concentrations, dedicated safety profiling for each ingredient will be mandatory. Silver nitrate also warrants caution due to potential argyria and tissue toxicity.
Conclusion and Next Steps
Decision: Hold
Rationale: This submission cannot be evaluated by the standard TxGNN drug repurposing pipeline because the product is a homeopathic combination formula without a DrugBank anchor, a conventional mechanism of action, or any registered indication. The absence of a TxGNN prediction is structurally expected, not a pipeline failure.
To proceed, the following is needed:
- Product identity clarification: Confirm whether this is a registered homeopathic product (with a manufacturer and intended indication) or an investigational mixture — the 23-component string does not correspond to any known single branded product.
- Ingredient-level decomposition: If repurposing is desired, each pharmacologically active ingredient (e.g., Valerian, Passiflora, Scutellaria) should be analysed individually as a separate TxGNN query.
- DrugBank ID assignment: At minimum, the primary active botanical(s) must be mapped to a DrugBank node before the TxGNN pipeline can be applied.
- Dose and concentration data: Homeopathic dilution levels (e.g., 6X, 30C) must be specified to determine whether any ingredient reaches a pharmacologically relevant concentration.
- Regulatory intent: Clarify whether the goal is to evaluate this product as a whole or to use it as a source of candidate actives for repurposing — these require fundamentally different analytical approaches.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.